Werner Creutzfeldt

Overview

Best Publications

• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

  M A Nauck;M M Heimesaat;C Orskov;J J Holst

  1937
  Citations

• Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.

  M. Nauck;F. Stöckmann;R. Ebert;W. Creutzfeldt

  1821
  Citations

• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36)amide in type 2 (non-insulin-dependent) diabetic patients

  M. A. Nauck;N. Kleine;C. Orskov;J. J. Holst

  1397
  Citations

• Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

  M A Nauck;E Homberger;E G Siegel;R C Allen

  1111
  Citations

• The incretin concept today.

  W. Creutzfeldt

  1036
  Citations

• Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. The German Study Group on Acute Biliary Pancreatitis

  Ulrich R. Fölsch;Rolf Nitsche;Rainer Lüdtke;Reinhard A. Hilgers

  833
  Citations

• Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

  B Willms;J Werner;J J Holst;C Orskov

  796
  Citations

• Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

  M A Nauck;E Bartels;C Orskov;R Ebert

  717
  Citations

• Natural course in chronic pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease.

  Paul Georg Lankisch;Annette Löhr-Happe;Jutta Otto;Werner Creutzfeldt

  615
  Citations

• Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients

  Werner O C Creutzfeldt;Nicola Kleine;Berend Willms;Cathrine Ørskov

  526
  Citations

• Histopathological classification of nonantral gastric endocrine growths in man.

  E. Solcia;C. Bordi;W. Creutzfeldt;Y. Dayal

  491
  Citations

• Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

  R Arnold;M E Trautmann;W Creutzfeldt;R Benning

  482
  Citations

• Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

  M. A. Nauck;D. Wollschläger;J. Werner;J. J. Holst

  477
  Citations

• Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis

  Regina Lamberts;Werner Creutzfeldt;Hans G. Strüber;Gorik Brunner

  443
  Citations

• Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets.

  W. E. Schmidt;E. G. Siegel;W. Creutzfeldt

  430
  Citations

• New developments in the incretin concept

  W. Creutzfeldt;R. Ebert

  395
  Citations

• Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis.

  I Albers;H Hartmann;J Bircher;W Creutzfeldt

  336
  Citations

• Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels

  W. Creutzfeldt;R. Ebert;B. Willms;H. Frerichs

  298
  Citations

• Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men.

  B Lembcke;W Creutzfeldt;S Schleser;R Ebert

  284
  Citations

• Pathomorphologic, biochemical, and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome)

  Werner Creutzfeldt;Rudolf Arnold;Corn Creutzfeldt;Norman S. Track

  268
  Citations